US · Healthcare · Diagnostics & Research
EPS came in at 3.02 against a street estimate of 2.72 — a beat of 11.0%.
Analysts rate Charles River Laboratories a hold (4 buy, 14 hold, 1 sell out of 19) with an average price target of $281.00.
CONFIDENT CRL beat Q2 expectations with first organic growth since Q3 2023. DSA rebooking accelerates with 1.2x net book-to-bill; Manufacturing margins expand 500bps. FY26 EPS guidance raised to $11.15–$11.45. Q2 2026 China RMS momentum offset North American RMS decline. Large pharma shifting R&D early-stage work to China but regulated safety assessment primarily Western-based. Analysts pressed AI timing (preclinical→IND), NHP capacity/margin cadence (Q3 vs. Q4), and China threat (biotech returns, pricing parity). Management emphasized multi-year AI ramp, controlled NHP scale-out, and regulated safety work as Western-anchored moat. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.08% |
| FMR Inc | 7.24% |
| Vanguard Capital Management, LLC | 6.71% |
| Amvescap Plc. | 5.02% |
| Vanguard Portfolio Management, LLC | 4.81% |
| Harris Associates L.P. | 4.69% |
| Allspring Global Investments Holdings, LLC | 4.18% |
| State Street Corp | 3.92% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $1,999.9 million (down from $2,01 | 2026-08-05 |
| Results announced · Q3 2026 CHARLES RIVER LABORATORIES — Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $1.00 billion (down 2.7% year-over-year from $1.03 billion | 2026-08-05 |
| Board / officer change · Q2 2026 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting Date: May 5, 2026 • Board Size: 12 directors ele | 2026-05-11 |
| Quarterly report · Q1 2026 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue Q1 2026: $995.8 million (vs. $984.2 million Q | 2026-05-07 |
| Results announced · Q2 2026 CHARLES RIVER LABORATORIES Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $995.8 million, up 1.2% reported from $984.2 million in Q1 2 | 2026-05-07 |
| Proxy statement · Q2 2026 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Directors — Vote | 2026-03-31 |
| Reg FD disclosure · Q1 2026 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company divesting CDMO and Cell Solutions businesses to GI Part | 2026-02-25 |
| Annual report FY2025 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. — FORM 10-K SUMMARY HEADLINE NUMBERS • Total 2025 revenue: $4.0 billion • Market value of voting comm | 2026-02-18 |
Readable in the app.
| Announcement | Date |
|---|---|
| Signed definitive agreements to divest CDMO, Cell Solutions, and European Discovery Services assets Charles River Laboratories announced plans to divest two business units in February 2026. First, it will sell its CDMO (contract development and manufacturing) and Cell Solutions businesses | 2026-02-25 |
| Q4 2025 DSA book-to-bill 1.1x; 2026 revenue and margin guidance updated Charles River Laboratories announced improving business trends and strategic acquisitions at the J.P. Morgan Healthcare Conference. Key highlights: The company's Discovery and Safety Assessm | 2026-01-13 |
| DSA net book-to-bill improving; positive momentum expected despite seasonal headwinds Charles River Laboratories announced at the Evercore Healthcare Conference on December 3, 2025 that its Discovery and Safety Assessment (DSA) business segment is showing improving momentum. | 2025-12-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Charles River Laboratories — free to start.
Google PlayApp StoreData updated 2026-09-18.